Orthocell has today announced global distribution partner BioHorizons has recorded a fast transition to first sales of Striate+™ in the key market of Canada
Petra Capital Research Report | September 2024
Petra Capital has released a research report valuing #Orthocell (ASX:OCC) at A$1.28 per share.
The report summarises Orthocell’s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.
The author noted:
“FY24 saw OCC’s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28/sh TP offering >3x upside.”
Orthocell submits Singapore Regulatory Application for Striate+™
Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).
Proactive | Interview with Paul Anderson
Orthocell Managing Director Paul Anderson speaks with Jonathan Jackson at Proactive about the Company’s seven regulatory applications in progress or planned, targeting approval in significant markets.
Orthocell Accelerates Global Market Expansion of Striate+™ and Remplir™ With Seven New Regulatory Applications either in progress or planned
Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned for its medical device platform products.
Quarterly Report – Period to 30 June 2024
Orthocell has today published its Quarterly Report for the period ended 30 June 2024.
Orthocell Receives Regulatory Approval to Commence Sales of Striate+™ in Canada
Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+™, in the key market of Canada.
The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
News of Orthocell’s record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business Review.
Business News | Orthocell posts record revenue
Orthocell’s record revenue for FY24 has been reported in Business News.
Proactive Interview | Record-breaking revenue for FY24
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company’s record-breaking revenue for the June 24 quarter and for FY24.